rtmark
LearnBonds.com

Gilead Sciences stock falls after poor trial results leaked

Gilead Sciences

Gilead Sciences (NYSE: GILD) stock price plunged below $80 after the World Health Organization (WHO) accidentally uploaded a report that said coronavirus treatment remdesivir (pictured) performed poorly in its first randomised clinical trial.

The  antiviral drug failed to reduce the virus presence in the bloodstream of COVID-19 patients in phase 3 clinical trial, said a report that was later removed from WHO’s website

Gilead said the document contained “inappropriate characterizations” and that the study’s findings were “inconclusive.”

Researchers in the Chinses trial studied 237 patients, given remdesivir to 158 and comparing their progress with the remaining 79. The drug also showed significant side effects in some, which meant 18 patients were taken off it. Scientists and investors had high hopes for the drug.

The biotech’s stock fell more than 9% on Thursday before gaining some group to close just over 4% down at $77.78. Shares have risen 25% this year.

US stock futures were down 0.7% after the S&P 500 and the Nasdaq turned negative at the close on Thursday in the wake of the widely-anticipated remdesivir report.

Gilead stock trading hit its highest level in more than two years last week after clinical trials from the University of Chicago indicated promising results in treating the coronavirus disease.

“We regret that the WHO prematurely posted information regarding the study, which has since been removed. The investigators in this study did not provide permission for publication of results,” a Gilead spokesperson said in response to the report published on the WHO website.

Gilead Sciences

The company said in a statement that the clinical trial was terminated amid small enrollment, which makes the study a poor guide in creating a statistically meaningful conclusions.

Last week, the University of Chicago report showed that 123 of 125 severe virus patents discharged within six days and only two patients took 10 days for complete stabilization.

Gilead Sciences

Gilead Sciences stock price has been making big moves on any news related to remdesivir, which had already generated promising results in the treatment of SARS and MERS epidemics. “Retail investors are “hungry” for good news on the virus. Those investors could be taking that and channeling it into buying shares,” Mike Bailey, director of research at FBB Capital Partners said.

If you are interested in buying Gilead Sciences stock ahead of final clinical trial data, you can check out our featured brokers here.

Trusted & Regulated Stock & CFD Brokers

Rating

What we like

  • 0% Fees on Stocks
  • 5000+ Stocks, ETFs and other Markets
  • Accepts Paypal Deposits

Min Deposit

$200

Charge per Trade

Zero Commission

Rating

64 traders signed up today

Visit Now

75% of investors lose money when trading CFDs.

Available Assets

  • Total Number of Stocks & Shares5000+
  • US Stocks
  • German Stocks
  • UK Stocks
  • European
  • ETF Stocks
  • IPO
  • Funds
  • Bonds
  • Options
  • Futures
  • CFDs
  • Crypto

Charge per Trade

  • FTSE 100 Zero Commission
  • NASDAQ Zero Commission
  • DAX Zero Commission
  • Facebook Zero Commission
  • Alphabet Zero Commission
  • Tesla Zero Commission
  • Apple Zero Commission
  • Microsoft Zero Commission

Deposit Method

  • Wire Transfer
  • Credit Cards
  • Bank Account
  • Paypall
  • Skrill
  • Neteller

Rating

What we like

  • Sign up today and get $5 free
  • Fractals Available
  • Paypal Available

Min Deposit

$0

Charge per Trade

$1 to $9 PCM

Rating

Visit Now

Investing in financial markets carries risk, you have the potential to lose your total investment.

Available Assets

  • Total Number of Shares999
  • US Stocks
  • German Stocks
  • UK Stocks
  • European Stocks
  • EFTs
  • IPOs
  • Funds
  • Bonds
  • Options
  • Futures
  • CFDs
  • Crypto

Charge per Trade

  • FTSE 100 $1 - $9 per month
  • NASDAQ $1 - $9 per month
  • DAX $1 - $9 per month
  • Facebook $1 - $9 per month
  • Alphabet $1 - $9 per month
  • Telsa $1 - $9 per month
  • Apple $1 - $9 per month
  • Microsoft $1 - $9 per month

Deposit Method

  • Wire Transfer
  • Credit Cards
  • Bank Account
Users should remember that all trading carries risks and users should only invest in regulated firms. Views expressed are those of the writers only. Past performance is no guarantee of future results. The opinions expressed in this Site do not constitute investment advice and independent financial advice should be sought where appropriate. This website is free for you to use but we may receive commission from the companies we feature on this site.
Avatar

Based in Saudi Arabia, Siraj has a strong understanding of and passion for accounting and finance. He has worked for international clients for many years on several projects related to the stock market, equity research and other business, accounting and finance related projects. Siraj is a published financial analyst on the world's leading websites including SeekingAlpha, TheStreet, MSN, and others.